Mesothelioma
208
38
56
78
Key Insights
Highlights
Success Rate
68% trial completion
Published Results
42 trials with published results (20%)
Research Maturity
78 completed trials (38% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
17.3%
36 terminated out of 208 trials
68.4%
-18.1% vs benchmark
5%
11 trials in Phase 3/4
54%
42 of 78 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 78 completed trials
Clinical Trials (208)
Agnostic Therapy in Rare Solid Tumors
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance
Rapid Autopsy and Procurement of Cancer Tissue
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Prospective Data Collection Initiative on Thoracic Malignancies
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.